Consulting and actuarial firm Milliman, Inc. said on Sept. 7 that it has acquired SkySail Rx, a pharmacy benefit technology firm. SkySail specializes in leveraging data to support pharmacy benefit pricing and contract management, allowing clients to “dynamically analyze large amounts of pharmacy data to drive efficiency and compliance,” according to a press release from the companies. “By joining with an independent firm like Milliman, SkySail can enhance our unique industry approach and generate natural business synergies that provide clients with an unparalleled blend of valuable objective advice and innovative tools for managing pharmacy benefits,” SkySail Principal Chuck Gamsu said in a statement about the deal. Financial terms of the transaction were not disclosed.

While the U.S. is still planning to widely distribute Pfizer Inc.’s COVID-19 booster shot starting the week of Sept. 20, the booster shot from Moderna, Inc. could lag a bit behind. That’s according to remarks made by White House Chief Medical Advisor Anthon Fauci, M.D. on CBS’s “Face the Nation” on Sept. 5. Fauci explained that only Pfizer may receive FDA approval for its booster in time for the planned end-of-September rollout, but Moderna should follow suit soon after. “So the bottom line is, very likely, at least part of the plan will be implemented, but ultimately the entire plan will be,” Fauci said.

Unlock the full version of this article by subscribing.

Log in | Learn More